• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Alzheimer's Disease Drug Development: Research and Development Ecosystem

Alzheimer's Disease Drug Development: Research and Development Ecosystem

9781108838665
598,44 zł
538,59 zł Zniżka 59,85 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 538,59 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
Alzheimers Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.
Szczegóły produktu
92931
9781108838665
9781108838665

Opis

Rok wydania
2022
Numer wydania
1
Oprawa
twarda
Liczba stron
574
Wymiary (mm)
183.00 x 259.00
Waga (g)
1340
  • Part I. Advancing Alzheimer therapies in a collaborative science ecosystem; Part II. Non-Clinical assessment of Alzheimer candidate drugs; Part III. Alzheimer clinical trials; Part IV. Imaging and biomarker development in Alzheimer drug discovery; Part V. Academic drug development programs; Part VI. Public-Private partnerships in Alzheimer drug development; Part VII. Funding and financing Alzheimer drug development.
Komentarze (0)